timothy sykes logo
GCTK Stock Draws Traders As Lokahi Pipeline And ai² Platform Advance Thumbnail
G Google News

GCTK Stock Draws Traders As Lokahi Pipeline And ai² Platform Advance

JACK KELLOGG•UPDATED SEP. 24, 2026, 8:33 AM ET
Reviewed by Tim Sykesand Fact-checked by Ellis Hobbs

GlucoTrack Inc. stocks have been trading up by 107.39 percent following upbeat sentiment around its non-invasive glucose monitoring technology.

Key Takeaways

  • Fresh convertible note financing gives GlucoTrack Inc. more runway to advance Lokahi Therapeutics’ LT-100 program and ai² platform, while introducing clear dilution risk around $3.12 and $7.50 levels.
  • After a July 14 business combination, Lokahi Therapeutics has become the core GCTK business, with LT-100 and ai² now center stage and GlucoTrack Technologies still focused on continuous glucose monitoring.
  • LT-100 manufacturing has started under GMP standards, backing a planned once-weekly, single subcutaneous injection osteoarthritis knee pain trial expected later this year.
  • The ai² ‘actual intelligence’ platform is expanding into Pipeline, Talent, and Accelerator divisions, built on 13 university ties and 45+ screened assets, several already under active diligence.
  • The ai² PIPELINE unit has landed its first outside client, Innovate GBM, converting it into a fee-for-service, revenue-generating asset-identification platform targeting brain tumors and glioblastoma.

Candlestick Chart

Live Update At 08:33:02 EDT: On Thursday, September 24, 2026 GlucoTrack Inc. stock [NASDAQ: GCTK] is trending up by 107.39%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

GCTK has traded like a classic small-cap biotech story: big moves, sharp retraces, and plenty of noise. From August 31, 2026, when GCTK closed near $4.25, the stock slid steadily to about $2.03 by September 23, 2026. That is roughly a 50% drawdown in three weeks, even as bullish Lokahi Therapeutics news hit the tape.

Intraday action tells the same story. On the heaviest recent session, GCTK spiked from the mid-$3s to the mid-$4s in premarket, with multiple five-minute candles showing wide ranges and quick reversals. That is textbook day-trader territory: liquidity for scalps, but also real trap potential if traders chase.

Fundamentals underline why GCTK behaves this way. The company posted quarterly net loss of about $3.8M and negative free cash flow near $3.6M. Cash was roughly $1.1M at period end, against total liabilities around $3.2M and negative equity. A current ratio near 0.5 shows balance-sheet stress.

More Breaking News

At the same time, GCTK’s price-to-earnings figure is meaningless for a loss-maker, and the tiny enterprise value near $11.35M signals how early the story still is. For traders, this is a binary-style biotech and platform setup, where news and liquidity, not traditional ratios, drive the tape.

Why Traders Are Watching GCTK Now

GCTK is in the middle of a full identity shift. What used to be a niche diabetes-device name is now, functionally, Lokahi Therapeutics plus the ai² platform, with the legacy GlucoTrack Technologies CGM program still alive but clearly in the back seat.

The market usually reacts when a micro-cap picks a lane. After the July 14 strategic business combination, the parent company made it clear: LT-100 for osteoarthritis knee pain and the ai² “actual intelligence” engine are now the main show. That gives traders a cleaner story to trade — a lead drug asset and a scalable sourcing platform.

On the drug side, GCTK has started GMP manufacturing of LT-100, a purified honeybee venom biologic aimed at non-opioid osteoarthritis pain relief. Importantly, Lokahi is shifting from a protocol that needed 15 intradermal injections to a once-weekly single subcutaneous shot. That is a big step toward a real-world product, and GMP manufacturing is often a key derisking milestone before human data.

On the platform side, Lokahi’s ai² system is being carved into three business lines — ai² Pipeline, ai² Talent, and ai² Accelerator. Backed by 13 universities and more than 45 screened assets, this gives GCTK multiple ways to source deals and potentially book revenue. The first fee-for-service client, Innovate GBM, is already on the books, paying for glioblastoma and brain tumor asset discovery through ai² PIPELINE.

Academic ties with San Diego State University’s Fowler College of Business and The University of Alabama’s Culverhouse College of Business feed even more deal flow into ai² Futures Lab. For traders, that means GCTK is not just a one-drug bet; it is building a low-cost “idea factory” that may spawn future catalysts.

Conclusion

For active traders, GCTK is exactly the kind of volatile, catalyst-driven setup that demands respect and tight risk control. The chart shows heavy selling from $4+ to the low $2s, even as Lokahi Therapeutics executes on GMP manufacturing, lines up a clinical protocol for LT-100, and signs new ai² collaborations. That disconnect between fundamentals-in-progress and price action is where disciplined trading plans matter most.

The recent $11.5M in convertible note financing gives GCTK more time to execute. About $4.5M of fresh cash and $4.5M in rolled notes extend the runway for LT-100 trials and ai² expansion, but the 22% discount, $3.12 conversion price, and $7.50 warrants define clear overhang zones. Any squeeze through those levels will likely draw even more day traders into GCTK.

At the same time, the Form 8-K filing reminds everyone that this is a real Nasdaq-listed company with ongoing material events, not just a message-board ticker. Lokahi’s growing university network, Innovate GBM as a paying ai² PIPELINE client, and the steady march toward an LT-100 trial give GCTK multiple shots on goal.

As Tim Sykes loves to say, “The key is not predicting which story will become the next big runner — it’s recognizing the pattern, trading the momentum, and cutting losses fast when the story breaks.” As millionaire penny stock trader and teacher Tim Sykes, says, “Consistency is key in trading; don’t let emotions dictate your trades.”. For GCTK, the story right now is clear: a tiny platform-and-therapeutics name trying to turn catalysts into staying power. Traders just have to decide how they want to trade the volatility.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”